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Summary
Objective
Obesity is associated with delayed insulin absorption upon subcutaneous (s.c.) dosing in
humans. The aim of this study was to investigate whether alterations in depot structure
and kinetics of the s.c. injection depot contribute to this delay.
Methods
Rats fed a high-fat diet (HFD) and low-fat diet (LFD) were included in a series of insulin
pharmacokinetic and imaging studies. Injection depots were visualized with micro
X-ray computed tomography imaging upon s.c. administration of insulin aspart mixed
with the contrast agent iomeprol, and insulin aspart exposure was measured by means
of luminescent oxygen channelling immunoassay.
Results
Body weight and fat mass were increased in rats fed an HFD vs. LFD (p < 0.05), whereas
the lean mass was not. The HFD group exhibited delayed insulin absorption from the s.c.
tissue (p< 0.001). This delay was associated with smaller injection depots upon s.c. dos-
ing (p < 0.05) and correlated with a slower depot disappearance from the s.c. tissue
(p < 0.05) compared with the LFD group. Depot disappearance from the s.c. tissue
was inversely correlated with body fat mass (p < 0.05).
Conclusions
Alterations in s.c. injection depot structure and kinetics may play a role in the obesity-
associated delay in insulin absorption.
Keywords: Injection depot, insulin pharmacokinetics, obesity, subcutaneous
administration.
Introduction
A number of factors have been reported to affect the rate
of insulin absorption from the subcutaneous (s.c.) tissue
and represent a source of pharmacokinetic variability in
people using s.c. insulin therapy (1). Obesity has been
associated with delayed insulin absorption upon s.c.
dosing in humans (2–5). This may partly be explained
by an obesity-associated decrease in s.c. blood flow
(2,4,5). The negative correlation between obesity and
decreased s.c. blood flow has been observed in both
fasting (2,4–9) and postprandial states (7,8,10), where
the latter is reflected by an attenuated rise in blood flow
in response to an oral glucose load or a mixed meal.
Both decreased capillary density (2,11) and impaired
vasomotor function (6) are thought to contribute to the
decrease in s.c. blood flow.
Other factors related to the s.c. micro-enviroment likely
also influence the insulin absorption profile. Upon s.c.
administration of insulin, an injection depot will form in the
s.c. tissue. The distribution of this depot determines both
the degree of depot dilution and the distance between the
insulin molecules and the s.c. blood capillaries (12,13).
Consequently, the more the depot distributes in the s.c.
tissue, the faster it likely absorbs into the circulation. This
notion is supported by our recent findings, where it was
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observed that larger size depots correlated with a faster
depot disappearance and that the rate of depot disap-
pearance correlated with insulin exposure in rats (14).
The aim of the present study was to investigate
whether alterations in depot distribution and kinetics
contribute to the obesity-associated delay in insulin ab-
sorption. The effect of obesity was investigated in rats
fed a high-fat diet (HFD) as compared with rats fed a
low-fat diet (LFD). The rats were included in a number of
pharmacokinetic and micro X-ray computed tomography
(μCT) studies, allowing us to investigate the link between
depot kinetics and insulin pharmacokinetics (14). As a
correlation between insulin pharmacokinetics and depot
kinetics was expected (14), it was hypothesized that
obesity would not only be associated with delayed insulin
absorption but also result in delayed disappearance of
the injection depot upon s.c. dosing.
Methods
Animals
All procedures performed in this study were approved by
the Danish Animal Experiment Inspectorate.
Figure 1 shows an overview of the study design.
Male Sprague Dawley rats (Charles River, Wilmington,
Massachusetts, USA) fed either an HFD or LFD were
included in the study. The rats fed an HFD received a diet
containing 60% fat from weaning to 22 weeks and 45%
fat from arrival at 22 weeks (D12492 and D12451, re-
spectively), whereas rats fed an LFD received a diet con-
taining 10% fat from weaning (D12450K, Research Diets,
Inc., New Brunswick, NJ 08901, USA). The effect of diet
on insulin absorption was investigated when the rats
were 33–34 weeks of age. The rats were subjected to
μCT scans at 36–38 weeks of age. Finally, intravenous
(i.v.) insulin profiles were obtained from 39-week-old rats.
Body composition
Body lean and fat mass were determined in all rats
using EchoMRI Body Composition Analyser (EchoMRI,
Houston, TX, USA) (15) when the rats were 26 or 30 weeks
of age (rats included in the neck and flank dosing studies,
respectively). Animal weights were recorded throughout
the study period.
Insulin absorption
Insulin absorption upon s.c. neck dosing was investigated
in HFD and LFD rats (n = 22 and n = 10, respectively).
Rats were s.c. dosed in the neck with 12-nmol insulin
aspart (20-μL NovoRapid®, Novo Nordisk, DK-2880
Bagsværd), and the blood was collected from the sublin-
gual vein at 5, 15 and 60 min post-dosing, enabling us to
assess the insulin levels prior to, at and after the expected
insulin peak plasma concentration (Cmax) (14). This exper-
iment was repeated five times for each rat, enabling us to
assess the pharmacokinetic variability across the two diet
groups (14).
Injection depot visualization
Eight rats from each diet group were included in a μCT
study for depot visualization, as previously described
(14). In short, rats were anaesthetized with isoflurane
and subsequently dosed in the neck with 20-μL insulin
aspart mixed in a ratio of 80/20 with the contrast agent
iomeprol (Novorapid® and Iomerol 350®, Bracco Imaging
Scandinavia, DK-2100 Copenhagen Ø). The rats were
then subjected to μCT scans at 1, 3, 7 and 13 min post-
dosing (Quantum XT, PerkinElmer, Waltham, USA), and
insulin exposure was determined by collecting the blood
from the tail at 5 and 15 min post-dosing. The experiment
was repeated three times for each rat.
Figure 1 Study design. Male Sprague Dawley rats were fed either a high-fat diet (HFD, n = 29) or low-fat diet (LFD, n = 16) from weaning until the
end of the study. Body composition was determined in all rats at week 26 and 30 (rats subcutaneous [s.c.] dosed in the neck and flank, respec-
tively, in the insulin absorption/micro X-ray computed tomography [μCT] study). When rats were 33–34 weeks of age, the effect of diet on insulin
absorption was investigated in rats fed an HFD (n = 22) and LFD (n = 10) upon s.c. administration of insulin aspart in the neck. All rats were sub-
jected to μCT scans at 36–38 weeks of age where they were s.c. dosed in the neck (HFD, n = 8; LFD, n = 8) or flank (HFD, n = 7; LFD, n = 6) with
insulin aspart mixed with iomeprol. Intravenous insulin aspart profiles were obtained from 39-week-old rats that had been dosed in the flank in
the μCT study (HFD, n = 6; LFD, n = 6). Animal weight was recorded throughout the study period.
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Based on the imaging results obtained from the rats
dosed in the neck, a similar study was performed in rats
dosed in the flank (HFD, n = 7; LFD, n = 6) following a
similar protocol. This was done in order to investigate
whether the findings on insulin pharmacokinetics and
depot kinetics in the neck also apply to other injection
regions. However, the scan time was prolonged to
17 min as a slower absorption rate upon flank dosing
was expected (14). The experiment was repeated four
times for each rat in order to increase study power, as
fewer rats were included compared with the neck dosing
μCT study. The rats dosed in the flank were selected
based on body composition and weight so that similar
differences in these parameters across the diet groups
were obtained as in μCT study with neck dosing. I.v.
insulin profiles were also investigated in these rats as
described next.
Intravenous insulin profiles
To rule out potential differences in insulin clearance be-
tween rats in the two diet groups, i.v. insulin profiles were
obtained from both diet groups in an insulin elimination
study (HFD, n = 6; LFD, n = 6). All rats were anaesthetized
with isoflurane prior to i.v. injection of insulin aspart
(1 nmol kg1), and blood was collected from the tail at
3, 7, 15, 30, 60, 120 and 180 min post-dosing.
Biochemical analysis
Quantification of plasma insulin aspart was performed
with luminescent oxygen channelling immunoassay tech-
nology (16).
Data handling and statistical analyses
Welch’s t-test – or where applicable, Mann–Whitney test
– was used to compare body weight and body composi-
tion between the diet groups. Statistical analyses of
depots and insulin pharmacokinetics were performed
as previously described (14): Volume and surface area
of the injection depots detected on μCT scans were
analysed in the imaging software Imaris (Bitplane AG,
Zurich, Switzerland), and all repeated measurements of
insulin exposure and depot structure were included in a
mixed-model analysis with day and rat as random factors.
The R-packages lme4 (17) and lmerTest (18) were used
for the analysis. CT scans where the entire depot was
not included (11 out of 397 scans) and pharmacokinetic
profiles from unsuccessful dosings (four out of 260
dosings) were excluded from the statistical analyses.
One rat was excluded from the analysis when evaluating
the i.v. profiles of insulin aspart, as sample contamination
was suspected. The correlation between fat mass and
decrease in depot volume/surface area over time was
investigated by means of linear regression analysis.
Statistical significance was defined by a p-value less
than 0.05, and all data are reported as mean ± SEM.
Means of repeated measurements in each group are
figured as the mean of the averages from all rats. Because
the depot volume and surface area were closely
correlated (R2 = 0.83, p < 0.001 by linear regression
analysis) and thus generally yielded comparable results
in terms of both depot kinetics and their correlation
with insulin exposure, only depot volume data are
included in the result section and figures. Finally, pharma-
cokinetic variability was estimated by simple methods by
calculating the coefficient of variation (CV) for insulin
exposure at 5, 15 and 60 min post-dosing for all rats
and is reported as the mean CV% with 95% confidence
interval.
Results
Body weight and composition
The HFD group had a significantly higher mean body
weight compared with the LFD group throughout the
study period: 777 ± 13 g vs. 658 ± 20 g and
869 ± 20 g vs. 731 ± 25 g when rats were 30 and
39 weeks of age, respectively (p< 0.05 or less). The mean
fat mass was also significantly increased in the HFD
group (p < 0.001, Figure 2a), whereas the mean lean
mass was not.
Insulin pharmacokinetics
There was an effect of diet intervention on the pharmaco-
kinetics of insulin aspart. This was reflected by signifi-
cantly lower mean insulin concentration at 5, 15 and
60 min post-dosing and reduced area under the curve
(AUC0–60 min, p < 0.01) in the HFD compared with the
LFD group (p < 0.001, Figure 2b). Similar results were
observed after weight-normalizing the insulin exposure
(p < 0.001, Figure 2c). Despite injection region, the mean
insulin concentration at 5 and 15 min post-dosing was
also lower in the HFD group during the μCT scan studies
when the rats were anaesthetized (p < 0.05 or less,
Figure 2d). The injection region also had an effect on
insulin pharmacokinetics, as rats dosed in the flank had
a significantly lower mean insulin concentration com-
pared with the rats dosed in the neck at 5 and 15 min
(p < 0.001, Figure 2d).
The total variability in exposure (CV%) for the HFD
and LFD groups at 5, 15 and 60 min was comparable:
Obesity Science & Practice Obesity and insulin injection depot kinetics A. K. J. Gradel et al. 283
© 2018 The Authors
Obesity Science & Practice published by John Wiley & Sons Ltd, World Obesity and The Obesity Society. Obesity Science & Practice
29 [23; 34] vs. 35 [29; 40], 23 [19; 28] vs. 26 [18; 33] and 37
[31; 43] vs. 40 [25; 56].
Evaluating the i.v. profiles of insulin aspart from the
two diet groups, no significant differences in a number
of pharmacokinetic parameters were found across the
diet groups, including the insulin concentrations at all
sampling time points, the volume of distribution (Vd),
the clearance rate (ClB) and the eliminations half-life
(T½, data not shown). Thus, the i.v. pharmacokinetic
profiles of insulin aspart seem to be comparable
between the two diet groups.
Depot kinetics
Examples of injection depots detected in an HFD and LFD
rat are shown in Figure 3a. As previously observed, the
highest concentration of iomeprol was located in the
centre of the injection depot upon s.c. dosing (14).
Figure 3b shows the changes in mean depot volume over
time in rats s.c. dosed in the neck, where it is evident
that the depot volume declines over time in both diet
groups. However, compared with the LFD group, the
injection depots in the HFD were initially smaller in size,
reflected by a significantly smaller mean depot volume
at 1 min post-dosing (p < 0.01). Moreover, these depots
disappeared slower from the s.c. tissue, as measured by
a smaller mean decrease in depot volume over time in
the HFD group (ΔVol1–3 min, ΔVol1–7 min and ΔVol1–13 min,
p < 0.05 or less).
Similar findings were observed when the rats were
dosed in the flank where the HFD group had significantly
smaller mean depot volumes at 1 and 3 min, larger
mean depot volumes at 13 and 17 min post-dosing and
a smaller mean decrease in depot volume over time
(ΔVol1–7 min, ΔVol1–13 min and ΔVol1–17 min, p < 0.05,
Figure 3c).
Despite diet group, the depot distribution and kinetics
differed across the two injection regions. This was
Figure 2 Body composition and insulin pharmacokinetics in rats fed a high-fat diet (HFD) or low-fat diet (LFD). (a) Body composition, fat and
lean mass, in rats fed an HFD (n = 29) and LFD (n = 16). (b) Insulin aspart levels in Sprague Dawley rats fed an HFD (n = 22) and LFD (n = 10)
upon subcutaneous (s.c.) administration of 20-μL (12-nmol) insulin aspart in the neck. (c) Insulin aspart levels after weight normalization in
Sprague Dawley rats fed an HFD (n = 22) and LFD (n = 10) upon s.c. administration of 20-μL (12-nmol) insulin aspart in the neck. (d) Insulin aspart
levels in HFD and LFD groups upon s.c. administration of 20-μL insulin aspart mixed with iomeprol in the neck (HFD, n = 8; LFD, n = 8) or flank
(HFD, n = 7; LFD, n = 6). Data are shown as mean ± SE, and for the repeated measurements group, means are figured as the mean of the av-
erages from all rats (b–d). **p < 0.01, ***p < 0.001 by Welch’s t-test or Mann–Whitney analysis (a) or repeated mixed-model analysis with day and
rat as random factors (b–d).
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Figure 3 Injection depot kinetics and correlation with insulin pharmacokinetics in rats fed a high-fat diet (HFD) or low-fat diet (LFD). (a) Arrows on
computed tomography images show subcutaneous (s.c.) neck depots from rats either fed an LFD (top: 60.6 mm3 in size) or HFD (bottom:
53.5 mm3 in size) at 1 min post-dosing with 20-μL insulin aspart mixed with iomeprol. (b) Depot volume over time in rats fed an HFD (n = 8)
or LFD (n = 8) upon s.c. administration of 20-μL insulin aspart mixed with iomeprol. (c) Depot volume over time in rats fed an HFD (n = 8) or
LFD (n = 8) upon s.c. administration of 20-μL insulin aspart mixed with iomeprol. (d) Depot volume over time in all rats fed an HFD (n = 8 and
n = 7 for neck and flank dosing, respectively) upon s.c. administration of 20-μL insulin aspart mixed with iomeprol. For the LFD animals, see
profiles in Figure 2b,c. (e) Decrease in depot volume over time (ΔVol1–13 min) was positively correlated with the insulin aspart levels at 15 min
post-dosing in LFD (n = 14) and HFD (n = 15) rats upon s.c. administration of 20-μL insulin aspart mixed with iomeprol (p < 0.001 by repeated
mixed-model analysis with day and rat as random factors). (f) Fat mass was negatively correlated with the average decrease in depot volume
over time (ΔVol1–13 min) in rats subjected to micro X-ray computed tomography scans and s.c. dosed with 20-μL insulin aspart mixed with
iomeprol (n = 29, p < 0.001 by linear regression analysis). Data in (b) to (d) are shown as mean ± SE, and means are figured as the mean of
the averages from all rats. **p < 0.01, ***p < 0.001 by repeated mixed-model analysis with day and rat as random factors (b–d).
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reflected by initially smaller depot volume and slower
depot disappearance in rats dosed in the flank vs. the
neck (p < 0.05 or less, Figure 3d for the HFD animals).
In order to assess whether the initial depot distribution
had an influence on the depot disappearance rate, the link
between depot volume at 1 min post-dosing and the
decrease in depot volume over time was investigated.
Results showed a significant correlation between initial
depot volume and the depot volumeover time, irrespective
of diet group and dosing region (Vol1 min vs. ΔVol1–13 min
and Vol1 min vs. ΔVol1–17 min, p < 0.01, data not shown).
There was a significant correlation between the speed
of depot disappearance and the insulin concentration,
irrespective of injection region and diet group (ΔVol1–3 min
vs. insulin 5 min, p < 0.05 or less; ΔVol1–13 min vs.
insulin 15 min, p < 0.001, Figure 3e). Thus, the faster
the depot disappeared from the s.c. tissue, the higher
the insulin exposure. Finally, it was also found that the
average depot disappearance rate was negatively
correlated with the total body fat mass, i.e. the higher
the fat mass, the slower the depot disappeared from the
s.c. tissue (neck dosing: p < 0.05 and R2 = 0.28; flank
dosing: p < 0.01 and R2 = 0.64; all dosings: p < 0.001
and R2 = 0.37, Figure 3f).
Discussion
Feeding of a diet rich in fat has been reported to be
accompanied by an expansion in adipose tissue mass in
rats (19–22). Accordingly, it was observed that rats fed
an HFD had a significantly higher body weight and fat
mass compared with rats fed an LFD, whereas the lean
mass was comparable across the diet groups, indicating
that the diet intervention used in this study can be used
to assess the effect of obesity on insulin pharmacokinet-
ics and depot structure in rats.
As reported in people with obesity (2–5), a delayed
insulin absorption was also observed in the rats fed an
HFD in this study. This may partly be attributed to
alterations in the distribution and kinetics of the injection
depot, because the depots from rats fed an HFD were
both smaller in size (indicating a smaller distribution upon
s.c. dosing) and disappeared slower from the s.c. tissue,
as measured by a smaller decrease in depot volume over
time. The more an injection depot distributes in the s.c.
compartment, the shorter the distance will likely be for
insulin to be absorbed by blood capillaries, because
insulin needs to travel through the extracellular matrix
prior to trans-capillary transport. An increased depot
distribution is also believed to result in increased and
faster dilution of the injection depot, thus yielding a higher
concentration of insulin monomers and dimers that are
associated with a faster absorption compared with insulin
hexamers, as previously discussed (13,14,23). Therefore,
it may not be surprising that a significant positive correla-
tion between the initial depot size and the speed of depot
disappearance was found (the larger the depot, the faster
the depot disappearance) and between the speed of
depot disappearance and insulin exposure (the faster
the depot disappears, the faster insulin is absorbed into
the circulation). Thus, the depot structure and kinetics
detected on the CT scans can be used to predict the
insulin exposure and may partly explain the obesity-
associated delay in insulin absorption. The fact that a
slow depot disappearance is linked to adipose tissue
mass is supported by the finding of a negative correlation
between body fat mass and the speed of depot
disappearance from the s.c. tissue.
Although the CT scans in this study only detect the
distribution of the contrast media and not of insulin
aspart, a correlation between depot kinetics and insulin
exposure was observed. Furthermore, a similar distribu-
tion of insulin aspart and another non-ionic water-soluble
contrast agent has been reported in pig s.c. tissue, as
previously discussed (14,24). Thus, it is reasonable to
assume that depots detected on the CT represent the
insulin injection depot.
Obesity is known to result in expansion of the adipose
tissue in both humans and rodents, occurring as a
result of adipocyte hypertrophy, hyperplasia or a combi-
nation of both depending on the region of interest
(20,21,25–27). Obesity could therefore be speculated to
increase the adipose tissue to interstitial fluid ratio in the
s.c. compartment, which to a larger degree may limit the
distribution of insulin aspart in the s.c. tissue, since the
insulin aspart preparation is hydrophilic and thus likely
only distributes in the interstitial fluid upon s.c. dosing.
In addition to limiting depot distribution, an expansion of
the adipose tissue mass in rats with diet-induced obesity
may also result in reduced s.c. blood flow, likely as a re-
sult of reduced capillary density and consequently capil-
lary area available for insulin diffusion, which may delay
depot disappearance and consequently insulin absorp-
tion. Furthermore, it still remains to be determined
whether these rats have impaired vasomotor function.
Blood flow measurements and tissue characterization
could thus be relevant for future studies in order to differ-
entiate between the relative contribution of s.c. blood
flow, injection depot structure or additional factors to
the delayed depot disappearance/insulin absorption.
Irrespective of diet group, injection into the neck vs. the
flank was associated with faster insulin absorption.
Furthermore, the regional differences in insulin pharma-
cokinetics also correlated with depot kinetics. In humans,
s.c. administration of insulin into the arm or abdomen is
associated with an accelerated absorption compared
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with administration into the thigh, irrespective of body
weight (2,28–31). Thus, as in humans with obesity, rats
fed an HFD not only exhibit a delayed insulin absorption
upon s.c. dosing, but the regional differences in insulin
pharmacokinetics are maintained (2). We have previously
found similar regional differences in insulin pharmacoki-
netics and depot kinetics in Sprague Dawley rats receiv-
ing standard chow (14), indicating that this phenomenon
may occur irrespective of diet choice/obesity status.
When considering the impact of the insulin injection
depot on insulin pharmacokinetics, this study supports
how improvements in pharmaceutical formulation or ad-
ministration technique can be used to diminish the
obesity-associated delay in insulin absorption. Although
their use is limited in the diabetic community, devices
such as jet injectors allow for the insulin depot to be dis-
persed in a spray-like manner in the s.c. tissue, thus in-
creasing its distribution. Accordingly, jet injectors have
been reported to be associated with beneficial effect in
people with obesity because the pharmacokinetic profile
of insulin to a lesser degree is affected by the insulin dose
or body weight (3). Simpler techniques that can be
used to facilitate a more rapid insulin absorption include
a dispersed injection strategy (32) or local massage of
the injection site (33,34). Adding excipients such as
hyaluronidase (35,36) or biochaperone (37) to the insulin
formulation also represents another mechanism by which
the depot distribution and diffusion in the s.c. tissue can
be enhanced. These strategies may all facilitate a faster
absorption from the s.c. tissue and consequently a faster
glucose-lowering effect in people with obesity.
Conclusion
In addition to increased body weight and fat mass, rats
fed an HFD exhibited delayed insulin absorption upon
s.c. dosing compared with rats fed an LFD. This delay
was associated with decreased depot distribution upon
s.c. dosing and correlated with a slower depot disappear-
ance. Thus, differences in depot structure and kinetics
may contribute to the obesity-associated delay in insulin
absorption.
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